Yonsei medical journal
-
Yonsei medical journal · May 2015
Comparative StudyMortality, length of stay, and inpatient charges for heart failure patients at public versus private hospitals in South Korea.
This study compared in-hospital mortality within 30 days of admission, lengths of stay, and inpatient charges among patients with heart failure admitted to public and private hospitals in South Korea. ⋯ We recommend that government agencies and policy makers continue to monitor quality of care, lengths of stay in the hospital, and expenditures according to type of hospital ownership to improve healthcare outcomes and reduce spending.
-
Yonsei medical journal · May 2015
Comparative StudyThe effect of specialized continuous renal replacement therapy team in acute kidney injury patients treatment.
Continuous renal replacement therapy (CRRT) has been established for critically ill acute kidney injury (AKI) patients. In addition, some centers consist of a specialized CRRT team (SCT) with physicians and nurses. To our best knowledge, however, ona a few studies have yet been carried out on the superiority of SCT management. ⋯ A well-trained CRRT team could be beneficial for mortality improvement of AKI patients requiring CRRT.
-
Yonsei medical journal · May 2015
Triglyceride is a useful surrogate marker for insulin resistance in Korean women with polycystic ovary syndrome.
To evaluate lipid profiles and liver enzymes as surrogate markers used for recognizing insulin resistance in Korean women with polycystic ovary syndrome (PCOS). ⋯ TG can be used as a useful marker for insulin resistance in Korean women with PCOS, especially for obese patients.
-
Yonsei medical journal · May 2015
Stimulating effect of a novel synthesized sulfonamido-based gallate ZXHA-TC on primary osteoblasts.
This study is intended to investigate the effects of plants or plant-derived antioxidants on prevention of osteoporosis through the maintenance of reactive oxygen species (ROS) at a favorable level. ⋯ This study may hold promise for the development of a novel agent for the treatment of osteoporosis.